PlainPharmaWatch

CMS Open Payments · Program Year 2024

Fennec Pharmaceuticals, Inc.

Fennec Pharmaceuticals, Inc. reported $215,036.74 across General Payments, Research, and Ownership to 1,115 physicians and teaching hospitals across 1,115 transactions.

$215.0K
All-tracks total
1,115
Transactions
1,115
Recipients
+$169.5K
General Payments vs PY2023

Fennec Pharmaceuticals, Inc. reported $215,036.74 across all CMS Open Payments tracks (General + Research + Ownership) to 1,115 physicians and teaching hospitals in Program Year 2024 - ranking #979 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $215,036.74, averaging $192.86 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer fennec-pharmaceuticals-inc Fennec Pharmaceuticals, Inc.

$215.0K · #979/1,925 · 0.0% industry · PY2024

  • TOT $215.0K
  • RANK #979
  • SHARE 0.0%
  • TXN 1,115
  • RCP 1,115
  • CAT 5
  • GEN $215.0K
  • ΔGEN +$169.5K
  • TOP1 47.7%
  • PY 2024

Nearest volume peer: Acarix USA Inc. ($215.3K)

Acarix USA Inc.$215.3KFennec Pharmaceuticals, Inc.…$215.0KLEO Pharma AS$214.7KPlanmeca USA, Inc.$214.2KPureLife, LLC$214.1K
All-tracks payment totals near Fennec Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Fennec Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Fennec Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $169.5K (+372.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2023: FENNEC PHARMACEUTICALS, INC.PY2024: Fennec Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$45.5KPY2024$215.0K
PY2023
$45,531.97
PY2024
$215,036.74

What the Data Shows for Fennec Pharmaceuticals, Inc.

In Program Year 2024, Fennec Pharmaceuticals, Inc. reported $215,036.74 in payments to 1,115 physicians and teaching hospitals across 1,115 individual transactions, an average of $192.86 per transaction and $192.86 per recipient. That total places Fennec Pharmaceuticals, Inc. at rank #979 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 5 general-payment categories charted below, "Consulting Fee" is the largest at $153.4K across 30 transactions, 71.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Fennec Pharmaceuticals, Inc.'s 5-category general-payment breakdown at $153.4K, 71.3% of the reported total.

Fennec Pharmaceuticals, Inc. reports 5 general-payment categories - the top three are Consulting Fee (71.3%), Food and Beverage (16.6%), and Honoraria (8.3%). The remaining 2 categories make up 3.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Fennec Pharmaceuticals, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$153.4K2. Food and Beverage$35.7K3. Honoraria$17.9K4. Travel and Lodging$7.6K5. Compensation for Services…$483.00
Payment Type Amount Transactions
Consulting Fee $153.4K 30
Food and Beverage $35.7K 1,068
Honoraria $17.9K 4
Travel and Lodging $7.6K 11
Compensation for Services Other Than Consulting $483.00 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $172,713.92 (80.3%) of $215,036.74 in this company's General Payments records across 718 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Fennec Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Ralph V Boccia$102.5KScott Penney$32.1KNoah Federman$17.1KVeronica Alana Vestal$12.8KRyuma Tanaka$8.2K
  1. 1

    Ralph V Boccia

    $102,510.93 across 20 reported transactions

  2. 2

    Scott Penney

    $32,144.80 across 23 reported transactions

  3. 3

    Noah Federman

    $17,063.31 across 9 reported transactions

  4. 4

    Veronica Alana Vestal

    $12,823.08 across 11 reported transactions

  5. 5

    Ryuma Tanaka

    $8,171.80 across 6 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Fennec Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Fennec Pharmaceuticals, Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Fennec Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Fennec Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.